WallStSmart

Innovative Eyewear Inc. (LUCY)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 225527% more annual revenue ($5.40B vs $2.39M). RMD leads profitability with a 27.5% profit margin vs 0.0%. RMD earns a higher WallStSmart Score of 70/100 (B).

LUCY

Hold

38

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.0

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LUCY.

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LUCY2 strengths · Avg: 9.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$3.07B8/10

Generating 3.1B in free cash flow

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

LUCY4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.89M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : LUCY

The strongest argument for LUCY centers on Price/Book, Free Cash Flow.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : LUCY

The primary concerns for LUCY are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

LUCY profiles as a value stock while RMD is a mature play — different risk/reward profiles.

LUCY carries more volatility with a beta of 3.23 — expect wider price swings.

RMD is growing revenue faster at 11.0% — sustainability is the question.

LUCY generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 38/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Innovative Eyewear Inc.

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Innovative Eyewear Inc. (LUCY) is at the forefront of the smart eyewear market, combining cutting-edge technology with contemporary design to serve a tech-oriented consumer base. The company's flagship Lucyd product line integrates audio capabilities and seamless connectivity, offering practical functionality while maintaining fashionable appeal. With an unwavering commitment to innovation and user experience enhancement, LUCY is poised to capitalize on the expanding demand for multifunctional wearables, positioning itself for substantial growth in the dynamic eyewear industry.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?